Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF) CEO Wayne Paterson speaks with Proactive after announcing the company has secured A$35 million in funding from a placement to various sophisticated and professional investors at an issue price of A$24.00 per share. AVR intends to use the proceeds to advance the clinical development of its DurAVR™ THV, the company’s first-in-class, biomimetic TAVR valve technology for the treatment of aortic stenosis, and general working capital purposes.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

jonathan@proactiveinvestors.com